Chimeric antigen receptors (CARs) combine a tumor antigen-recognition domain with intracellular signaling domains, enabling recognition and killing of tumor cells in a major histocompatibility complex (MHC)-independent manner (1). This evidence concerns the gene HLA-C and neoplasm.